BioCentury | Sep 15, 2014
Clinical News

C16G2: Phase II data

...start a dose-ranging Phase IIb trial of C16G2, but could not be reached for details. C3 Jian Inc....
BioCentury | Mar 24, 2014
Financial News

C3 Jian completes venture financing

C3 Jian Inc. , Marina del Rey, Calif. Business: Infectious, Diagnostic, Dental Date completed: 3/17/14 Type: Venture financing Raised: $60.5 million Investors: Renaissance Holding; Delta Dental; existing investors; new investors WIR Staff...
BioCentury | Mar 17, 2014
Financial News

C3 Jian raises $60.5 million in series D

...Company. New investor Delta Dental also participated along with other undisclosed new and existing investors. C3 Jian...
BioCentury | Mar 17, 2014
Clinical News

C16G2: Phase II started

...and rinse applications of C16G2 administered using a dental tray, electric toothbrush or manual toothbrush. C3 Jian Inc....
BioCentury | Sep 2, 2013
Clinical News

C16G2: Phase I data

...single oral rinse of C16G2 led to no treatment-related, severe or serious reported adverse events. C3 Jian Inc....
BioCentury | Feb 25, 2013
Clinical News

C16G2: Completed Phase I enrollment

...a double-blind, dose-escalation, U.S. Phase I trial to evaluate a single oral rinse of C16G2. C3 Jian Inc....
BioCentury | Mar 5, 2012
Financial News

C3 Jian completes venture financing

...2/27/12 Type: Venture financing Raised: $30 million Investors: Wyssta Investments; Renaissance Health Services; Corvesta Note: C3 Jian...
BioCentury | Feb 28, 2012
Financial News

C3 Jian raises $30 million

...in a series C round from existing investors Wyssta Investments; Renaissance Health Services; and Corvesta. C3 Jian...
Items per page:
1 - 8 of 8
BioCentury | Sep 15, 2014
Clinical News

C16G2: Phase II data

...start a dose-ranging Phase IIb trial of C16G2, but could not be reached for details. C3 Jian Inc....
BioCentury | Mar 24, 2014
Financial News

C3 Jian completes venture financing

C3 Jian Inc. , Marina del Rey, Calif. Business: Infectious, Diagnostic, Dental Date completed: 3/17/14 Type: Venture financing Raised: $60.5 million Investors: Renaissance Holding; Delta Dental; existing investors; new investors WIR Staff...
BioCentury | Mar 17, 2014
Financial News

C3 Jian raises $60.5 million in series D

...Company. New investor Delta Dental also participated along with other undisclosed new and existing investors. C3 Jian...
BioCentury | Mar 17, 2014
Clinical News

C16G2: Phase II started

...and rinse applications of C16G2 administered using a dental tray, electric toothbrush or manual toothbrush. C3 Jian Inc....
BioCentury | Sep 2, 2013
Clinical News

C16G2: Phase I data

...single oral rinse of C16G2 led to no treatment-related, severe or serious reported adverse events. C3 Jian Inc....
BioCentury | Feb 25, 2013
Clinical News

C16G2: Completed Phase I enrollment

...a double-blind, dose-escalation, U.S. Phase I trial to evaluate a single oral rinse of C16G2. C3 Jian Inc....
BioCentury | Mar 5, 2012
Financial News

C3 Jian completes venture financing

...2/27/12 Type: Venture financing Raised: $30 million Investors: Wyssta Investments; Renaissance Health Services; Corvesta Note: C3 Jian...
BioCentury | Feb 28, 2012
Financial News

C3 Jian raises $30 million

...in a series C round from existing investors Wyssta Investments; Renaissance Health Services; and Corvesta. C3 Jian...
Items per page:
1 - 8 of 8